The Dry Horizons Symposium
Uniting clinical leaders and industry innovators to tackle significant challenges in the dry eye market.
With the rising prevalence of dry eye disease, the shortcomings of existing treatments, as well as new opportunities for advancing clinical pathways based on recent successful therapies, this symposium will provide in-depth coverage of the global landscape of Dry Eye and the opportunity for further innovation. From the impact of technology use on eye health, to unexplored therapeutics, to accelerating research and development, this new event will showcase the urgent need for innovative clinical solutions to benefit current and future patients.
About Ora Inc.
Ora is the world’s leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 85 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.
About Ophthalmology Innovation Source:
The Ophthalmology Innovation Summit launched in 2009 as the first event to showcase novel therapies in development for unmet needs in ophthalmic disease and vision disorders.
Since then, the mission of uniting entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals to facilitate a powerful exchange of information and connections to drive innovation has evolved. Over the course of the following decade, OIS successfully expanded with additional high-caliber summits focused on the anterior segment, retina and optometry.